Tuberkulose-Erreger sind zunehmend unempflindlich gegen Antibiotika. “Wir in der Schweiz können nicht sagen, Tuberkulose ginge uns nichts an” Marc Gitzinger, BioVersys AG Link to Article
Beobachter 10/2017: Die Tuberkulose überlistet. Ein Interview mit Marc Gitzinger Read More »
Health Needs Tuberculosis (TB) is the world’s leading infectious disease killer. It killed 1.7 million people in 2016 and 10.4 million people developed active TB in the same year—490,000 of TB cases are multidrug-resistant (MDR-TB) with an additional 110,000 resistant to at least one drug, meaning they do not respond to first line treatments and
AMR Industry report and case study BioVersys Read More »
BASEL, Switzerland and GREENWICH, Connecticut, March 7, 2017 Bioversys AG and Aptuit today announced the start of a joint collaboration aimed at the identification and validation of novel targets and molecules for Gram-negative bacteria. Aptuit and BioVersys hope that innovative approaches can address antibiotic resistance in the treatment of serious infections. BioVersys is focused on the development of
BioVersys and their collaborators in Lille (represented by Professor Nicolas Willand) win the 8th Innovation prize at the Innovation Days in Paris, October 3rd, 2016! The Innovation Prize aims to promote innovation in the field of Life Sciences. The project was selected among 259 applications submitted from 38 countries after three phases of intense assessment
Marc Gitzinger wins innovation prize for BioVersys AG Read More »
